Published framework
CRISPR preclinical-to-clinical decision tree
Published a CRISPR preclinical-to-clinical decision-tree framework with Johns Hopkins Carey Business School affiliation, combining IND/CTA pathway comparisons across FDA, EMA, MHRA, PMDA, and NMPA with decision points for editing specificity, long-term safety, and in-vivo versus ex-vivo risk.
